Skip to content
Assyro AI
Purple Book reference family · 351(a) biologic

onasemnogene abeparvovec-brve (ITVISMA)

onasemnogene abeparvovec-brve is an FDA-licensed reference biologic from Novartis Gene Therapies, Inc..

351(a) biologicBLA 125856 Novartis Gene Therapies, Inc.
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2025

Reference product

Originator biologic
Ask AI
351(a)BLA 125856

ITVISMA onasemnogene abeparvovec-brve

Novartis Gene Therapies, Inc.

View full reference-product record
Approved
Marketing
Rx
Center
CBER
Patents
None listed

Exclusivity & patent cliffs

Protection horizon
Ask AI
  1. Reference approval

    Approval date of the reference onasemnogene abeparvovec-brve product.

    1 yr ago

onasemnogene abeparvovec-brve: frequently asked questions

Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.

Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for onasemnogene abeparvovec-brve.

Related FDA reference tools

Assyro Intelligence

Ask anything about onasemnogene abeparvovec-brve

Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.

  • PubMed
  • ClinicalTrials.gov
  • FDA
  • Health Canada
  • EMA
  • ICH

Evaluating for a team? Book a demo